The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 38 | — | 20.1x | Near average | |
Growth | 72 | 1199.6% | 5.6% | Above average | |
Quality | 41 | -59.9% | 7.6% | Near average | |
Safety | 59 | 1.9x | 0.4x | Near average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Ovid Therapeutics Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Ovid Therapeutics Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Ovid Therapeutics stock shows complete stability in the average target price at 5.5 dollars over the timeframes (past 1, 7, and 30 days), with a consensus from 6 analysts. Despite the gap between the low (4 dollars) and the high (7 dollars), the absence of any recent adjustments in ratings indicates a state of anticipation awaiting new catalysts or upcoming clinical results.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.